Demographic factors, genetic factors, and cognitive reserve influence SCD, which in turn increases the risk of Alzheimer’s disease (AD). The study presented by Dr Giulia Giacomucci (University of Florence, Italy) aimed to analyse how sex might modulate the influence of cognitive reserve on SCD [1]. The study included 381 patients with SCD aged >40, who had self-reported symptoms of cognitive decline during ≥6 months. Patients underwent clinical evaluation, neuropsychological assessment, the Test di Intelligenza Breve (TIB) to evaluate premorbid intelligence, the Memory Assessment Clinics-Questionnaire (MAC-Q) to evaluate cognitive complaints, Hamilton Depression Rating Scale (HDRS) to evaluate depressive symptoms, and ApoE genotyping.
The cohort contained about twice as many women as men: 68.7% versus 31.3%. Women were younger at SCD onset and at study baseline (P=0.02), had less years of education (P=0.007), lower TIB scores (P<0.001), and higher HDRS (6.3 vs 5.12; P=0.007) and MAC-Q scores (26.3 vs 25.0; P=0.012). The number of years of education was inversely associated with age at onset only in women (ρ=0.259; P<0.001). The only factor influencing MAC-Q was sex. TIB was directly associated with MAC-Q only in men (ρ=-0.292; P<0.005). Sex and cognitive reserve influenced severity of cognitive complaints, which was higher in women. In men, higher cognitive reserve was associated with worse cognitive complaints in a linear fashion.
This result contradicts previous studies reporting that less educated individuals showed a higher degree of cognitive complaints. Dr Giacomucci said this discrepancy may be explained by the different cognitive reserve proxy, and/or the different recruitment method. “Sex and cognitive reserve interact in influencing age at onset and severity,” Dr Giacomucci concluded. She added it is not possible to describe the relationship between sex and cognitive reserve in SCD in a complete and uniform model.
- Giacomucci G, et al. Sex influences the effect of cognitive reserve on subjective cognitive decline. OPR-043, EAN 2021 Virtual Congress, 19–22 June.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Expanding precision medicine to stroke care Next Article
Inability to recognise disgust as first cognitive symptom of ALS »
« Expanding precision medicine to stroke care Next Article
Inability to recognise disgust as first cognitive symptom of ALS »
Table of Contents: EAN 2021
Featured articles
Letter from the Editor
COVID-19
First evidence of brainstem involvement in COVID-19
Cognitive/behavioural alterations persistent after COVID-19
Neural base of persistent hyposmia after COVID-19
Neurological symptoms and complications of COVID-19 affect outcomes
Cerebrovascular Disease
Intracerebral haemorrhage only slightly increases mortality in COVID-19 patients
Stroke with covert brain infarction indicates high vascular risk
Expanding precision medicine to stroke care
Dexamethasone not indicated for chronic subdural haematoma
Cognitive Impairment and Dementia
Severe outcomes of COVID-19 in patients with dementia
Promising diagnostic accuracy of plasma GFAP
Sex modulates effect of cognitive reserve on subjective cognitive decline
Hypersensitivity to uncertainty in subjective cognitive decline
Epilepsy
Minimally invasive device to detect focal seizure activity
‘Mozart effect’ in epilepsy: why Mozart tops Haydn
Migraine and Headache
Factors associated with decreased migraine attack risk
Pregnant migraine patients at higher risk of complications
Occipital nerve stimulation in drug-resistant cluster headache
Rhythmicity in primary headache disorders
Multiple Sclerosis and NMOSD
Typing behaviour to remotely monitor clinical MS status
Alemtuzumab in treatment-naïve patients with aggressive MS
No higher early MS relapse frequency after stopping ponesimod
Good long-term safety and efficacy of inebilizumab in NMOSD
Neuromuscular Disorders
Inability to recognise disgust as first cognitive symptom of ALS
Pathogenic T-cell signature identified in myasthenia gravis
Parkinson’s Disease
Levodopa-carbidopa intestinal gel in patients with advanced PD
New Frontier – Navigated Transcranial Ultrasound
Exploring the possibilities
Related Articles
August 18, 2021
Safinamide improves non-motor symptoms in PD
August 18, 2021
Cognitive/behavioural alterations persistent after COVID-19
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com